CEBP Frontiers in Cancer Prevention Research - 2008 Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on November 28, 2006
This Article
Right arrow Full Text (Online First [PDF])
Right arrow All Versions of this Article:
1055-9965.EPI-06-0509v1
15/12/2370    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walker, M. S.
Right arrow Articles by Fisher, E. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, M. S.
Right arrow Articles by Fisher, E. B.
©American Association for Cancer Research
Cancer Epidemiology Biomarkers & Prevention, 10.1158/1055-9965.EPI-06-0509


Research Articles

Smoking Relapse during the First Year after Treatment for Early-Stage Non-Small-Cell Lung Cancer

Mark S. Walker 1*, Damon J. Vidrine , Ellen R. Gritz , Randy J. Larsen , Yan Yan , Ramaswamy Govindan , Edwin B. Fisher

1 1Departments of Medicine, 2Psychology, and 3Surgery, Washington University School of Medicine, St. Louis, Missouri; 4Department of Behavioral Science, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; and 5Department of Health Behavior and Health Education, School of Public Health, University of North Carolina, Chapel Hill, North Carolina

* To whom correspondence should be addressed. E-mail: mwalker{at}im.wustl.edu.


   Abstract

Background: Non-small-cell lung cancer patients who continue to smoke after cancer diagnosis are more likely to experience disease recurrence, decreased treatment efficacy, and treatment complications. Despite this, many continue to smoke, with estimates ranging from 13% to ~60%.

Methods: Participants were 154 early-stage, non-small-cell lung cancer patients who had smoked within 3 months before surgery. Patients were followed for 12 months after surgery to assess smoking status and duration of continuous abstinence after surgery. Predictors included medical, smoking history, psychosocial, and demographic characteristics.

Results: At some point after surgery, 42.9% of patients smoked; at 12 months after surgery, 36.9% were smoking. Sixty percent of patients who lapsed did so during the first 2 months after surgery. Smoking at follow-up was predicted by shorter quit duration before surgery, more intense Appetitive cravings (expectation of pleasure from smoking), lower income, and having a higher level of education. Time until the first smoking lapse was predicted by shorter quit duration before surgery, more intense Appetitive cravings to smoke, and lower income. Among those who lapsed, greater delay before the lapse was associated with abstinence at the 12-month follow-up assessment.

Conclusions: Nearly half of non-small-cell lung cancer patients return to smoking after surgery if they have recent smoking histories. Most initial lapses happen within 2 months and occur in response to more recent smoking and more intense cravings. Findings suggest that interventions to prevent relapse should target those who wait until cancer surgery to quit smoking and should be started as soon as possible after treatment. (Cancer Epidemiol Biomarkers Prev 2006;15(12):2370-7)

Key Words: lung cancer, tobacco, smoking, behavioral prevention, nicotine dependence




This article has been cited by other articles:


Home page
JCOHome page
N. L. Benowitz
Cigarette Smoking and the Personalization of Irinotecan Therapy
J. Clin. Oncol., July 1, 2007; 25(19): 2646 - 2647.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.